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Abstract
Background: Infertility is a major problem in sickle cell disease patients, especially in males. In addition to low
serum testosterone, other abnormalities involving the accessory sex organs, such as the seminal vesicles and the
prostate gland, as well as marked decrease in ejaculate volume may be observed in male HbSS patients. Hence,
the need to study the role of sex hormones as a cause of infertility in male HbSS patients.
Methods: An unmatched case-control study was performed using seventy-five consenting subjects from Lagos
University Teaching Hospital. These included 47 patients with haemoglobin phenotype SS from the Sickle cell clinic
and 28 volunteered medical students and members of staff with haemoglobin phenotype AA. Demographic data
were obtained using a self-administered questionnaire. A total of 5 mls of blood was collected from each subject
between 9.00 am & 11.am, and assayed for serum testosterone concentration.
Results: The concentrations of serum testosterone in HbSS patients ranged from 0.2 to 4.3 ng/ml with a mean of
1.28 ± 0.72 ng/ml whilst the values in HbAA controls ranged from 1.2 to 6.9 ng/ml with a mean of 2.63 ± 1.04 ng/
ml. Seven (25.0%) of the 28 controls had serum testosterone concentration lower than the quoted reference
(normal) range whereas 44 (93.6%) of the 47 HbSS subjects had serum testosterone concentration lower than the
reference range.
Conclusion: Overall, subjects with HbSS have significantly lower mean serum testosterone than HbAA controls.
Background
Homozygous sickle cell disease is a genetic disorder
caused by a point mutation in the beta globin gene,
which results in the substitution of valine for glutamine
[1]. The resultant haemoglobin variant, HbS, poly-
merizes at low oxygen tension, causing the characteristic
sickle deformity of the red cells, the main aetiopathoge-
netic feature of this disease [2].
Infertility in Sickle cell disease
Infertility is a known complication in males with sickle
cell disease. This has been attributed to relative primary
gonadal failure, impotence, and priapism, delayed or
impaired sexual development [3]. The ejaculate volume,
sperm motility, sperm density, and normal sperm mor-
phology were significantly reduced in the patients when
compared with the control subjects [4]. Most impor-
tantly, primary testicular failure is characterized by low
levels of testosterone in which infertility results mainly
from diseases or conditions that primarily affect and
destroy the testis [5]. The low levels of testosterone
results in reduction of fertility which is aggravated by
impotence, secondary to earlier priapism [6].
Oligospermia due to local ischaemia caused by sickling
phenomenon and tissue hypoxia have been reported in
sickle cell disease patients [7]. Hypopituitarism reported
in HbSS disease, results from intravascular thrombosis
and pituitary infarction [8]. Sickle cell disease is asso-
ciated with high folate demand. This with zinc * Correspondence: ajoke_clinic@yahoo.co.uk
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mary gonadal dysfunction [9].
It is noted that reduction in semen volume, sperm
count and motility in sickle cell male patients are prob-
ably attributed to low level of testosterone [10].
The aim was to determine the testosterone levels in
sickle cell disease male patients compared with levels in
HbAA controls, using enzyme linked immunosorbent
assay (ELISA).
Methods
This was an unmatched case-control study using homo-
zygous sickle cell disease male patients attending the
sickle cell clinic of the Lagos University Teaching Hos-
pital and HbAA controls consisting of apparently
healthy medical students and members of staff from the
same health institution. Seventy-five subjects between 15
- 45 years age groups, consisting of forty seven (47)
male patients with homozygous sickle cell disease
(HbSS) and twenty-eight (28) volunteered male controls
with HbAA phenotype were recruited consecutively
between April 2008 to August 2008. Approval was
obtained from the institution’s research and ethics com-
mittee. Consenting participants were asked and aided to
fill the structured questionnaires, consisting of demogra-
phy information and history of smoking, consumption
of alcohol, drug use apart from the usual routine medi-
cations for sickle cell disease patients and medical pro-
blems such as hypertension, diabetes mellitus and
rheumatoid arthritis.
Exclusion criteria
1) Patients with homozygous sickle cell disease not
in steady state .2) Subjects on special drugs such as
chemotherapy, anabolic steroids, cimetidine, spirono-
lactone, phenytoin, sulfasalazine and nitrofurantoin
that could affect serum testosterone assay.3) Subjects
with history of recent or chronic consumption of
alcohol and smoking of cigarette.4) Healthy controls
with obvious medical problems such as diabetes mel-
litus, hypertension, rheumatoid arthritis,5) Grossly
haemolyzed, lipaemic, icteric or improperly stored
serum.
Inclusion criteria
1) HbSS patients in steady state.2) Apparently healthy
HbAA control groups with no obvious medical pro-
blems such as diabetes mellitus, hypertension, rheuma-
toid arthritis
Collection of sample
A total of 5 mls of blood sample was collected in an
unanticoagulated bottle from Hb SS subjects during
period of steady states and the Hb AA controls. All
samples were collected between 9.00 and 11.00 am due
to the circadian rhythm of testosterone. The sera were
separated and stored at -20°c on the same day of collec-
tion until ready to be analyzed for testosterone.
Analysis of Data
The descriptive data were given as means ± standard
deviation (SD). Distributions of serum testosterone con-
centrations in cases and controls were compared using
independent sample t-test. The differences were consid-
ered statistically significant when p value obtained was <
0.05.
Results
A total of 75 subjects consisting of two groups, 47
HbSS and 28 HbAA (controls) were recruited for this
study. The age range was 17 to 41 years. Most HbSS
subjects were in the 20-24 years age group (51.1%)
with a mean age of 24.25 ± 5.27 years while most of
the controls were in the age group 30-34 years (39.3%)
with a mean age of 29.5 ± 2.12 years (p = 5.16 × 10
-5)
[Table 1].
The concentrations of serum testosterone for homozy-
gous sickle cell disease patients ranged from 0.2 to 4.3
ng/ml whereas the concentrations of serum testosterone
for HbAA patients ranged from 1.2 to 6.9 ng/ml. Most
of the HbSS patients, 44 out of 47 (93.6%) had serum
testosterone concentrations below the normal range
when compared with HbAA of 7 out of 28 (25.0%)
[Table 2]. The mean serum testosterone concentration
for HbAA controls of 2.63 ± 1.04 ng/ml was signifi-
cantly higher than mean of 1.28 ± 0.72 ng/ml obtained
for HbSS patients (p = 2.8 × 10
-7) [Table 2]. The refer-
ence range provided by the manufacturer (BIOCHECK,
INC) was 2 to 10 ng/ml.
There was no statistically significant difference in the
serum testosterone level when the data were stratified
by age-group (17-22, 23-28 and 29-above) (Table 1)
However, subjects less than 22 years old and older
than 29 years old with normal haemoglobin phenotype
had significantly higher mean serum testosterone con-
centration than those homozygous sickle cell disease
patients of the same age groups [p = 0.000 < 0.05.]
Table 2
The mean age of puberty for sickle cell anaemic
(HbSS phenotype) patients was 17.65 ± 1.86 years which
was significantly higher than the mean age of puberty
for the controls (HbAA phenotype), 14.1 ± 0.93 years (p
= 5.6 × 10
-13).
Twenty-five (53.2%) HbSS subjects had history of
priapism; most commonly seen in the ages between 10
and 14 years while the remaining 22 (46.8%) had no his-
tory of priapism.
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The result of this study showed that serum testosterone
levels are significantly reduced in sickle cell male
patients compared to matched controls. This finding is
similar to work done by Dada et al [8], Abbasi et al [10]
and Parshad et al.[11] The low levels of serum testoster-
one may be a reflection of hypogonadism secondary to
hypopituitarism [12]. Hypopituitarism in HbSS disease
may result from intravascular thrombosis and pituitary
infarction [12].
Other contributing factors like repeated testicular
infarction which may be total or segmental has a prob-
able underlying mechanism of testicular failure,
impaired fertility, and reduced serum testosterone in
patients with sickle cell disease [12,13]. The low testos-
terone levels may manifest as decreased muscle mass
and bone mineral density, increased fat mass, central
obesity, insulin resistance, decreased libido and energy,
irritability, and dysphoria [13].
Most of the HbSS subjects were relatively younger with
mean age of 24.2 years compared with HbAA controls
(29.5 years). Although, cases and control groups differ very
significantly by age, the mean serum testosterone concen-
tration in controls for those below 22 years old and above
29 years old was significantly higher than homozygous
sickle cell disease patients of the same age groups. From
the foregoing, the difference may be explained by small
sample size of the control subjects relative to the cases
group. Moreover, this difference in age with relationship to
the serum testosterone concentration may be reduced
slightly because testosterone levels tend to fall with age
with the decline beginning at about age 30 [14,15].
Most of the HbSS subjects studied had late onset of
puberty with a mean age of 17.65 years compared with
HbAA controls (14.1 years) similar to findings reported
by Consuelo et al [16].
Twenty-five (53.2%) of the HbSS patients had history
of priapism with ages between 10 and 14 years most
commonly affected. This finding concurs with other stu-
dies done by Ibidapo et al in Lagos, Nigeria, Farrukh
Sheh and Renard Davies in London, UK who recorded
relatively high values ranging from 40% to 67.0% cases
of priapism in sickle cell anaemic patients [17,18].
Agbaraji et al and Osegbe D.N. et al reported that the
fertility indices such as ejaculate volume, sperm motility,
sperm density, and normal sperm morphology were sig-
nificantly impaired in sickle cell anaemic patients when
compared with the controls, which further corroborated
the role of reduced serum testosterone concentration in
the investigation of infertility cases [4,19].
Some of the limitations of our study are, appreciable
numbers (25.0%) of matched HbAA controls had serum
testosterone levels below the manufacturer’sq u o t e d
reference range and the facts that samples could not be
collected for serum testosterone levels in all the HbSS
and HbAA subjects at the same time. This is of impor-
tance because testosterone concentrations falls with age
with the decline beginning at about age 30 and is often
progressive, leading to levels in the 60 s-80 s that are
below the reference range for young adults [13].
Table 1 Age and Serum Testosterone Concentrations in HbSS and HbAA Subjects
AGE(Years) HBSS SUBJECTS HBAA SUBJECTS All subjects
n LOW* NORMAL** n LOW* NORMAL **
15-19 12 12 - - - - 12
20-24 24 23 1 7 2 5 31
25-29 5 3 2 8 2 6 13
30-34 4 4 - 11 3 8 15
35-39 1 1 - 1 - 1 2
40 and above 1 1 - 1 - 1 2
TOTAL 47 44 (93.6%) 3(6.4%) 28 7 (25.0%) 21(75.0%) 75(100%)
Reference Concentrations of Serum Testosterone = 2 to 10 ng/ml
*Low serum testosterone level ≤ 2 ng/dl
**Normal serum testosterone level > 2 ng/dl.
Table 2 Age and Mean Serum Testosterone Concentrations of HbSS and HbAA Subjects
Age Groups HbSS HbAA
(Years) Numbers of subjects Mean Serum ± SD
Testosterone(ng/ml)
Numbers of subjects Mean Serum ± SD
Testosterone(ng/ml)
17-22 23 1.139 ± 0.575 3 2.833 ± 0.551
22-28 13 1.638 ± 0.973 8 2.228 ± 0.565
29-above 11 1.073 ± 0.514 17 2.753 ± 1.257
Total Average 47 1.283 ± 0.514 28 2.625 ± 0.791
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one levels in those affected controls may be attributed
to poor cold chain storage system from the country of
manufacture to Nigeria. Improper storage especially in
conditions of erratic power supply which is found in the
developing country like Nigeria, diurnal rhythm of tes-
tosterone secretions, environmental influences and tak-
ing of androgen suppressing drugs [20]. Although, the
effects of these factors were minimal in our study as evi-
denced by validation tests done using sets of controls
provided by the manufacturer. In addition, supposedly
healthy controls may be suffering from diseases such as
diabetes mellitus, rheumatoid arthritis and thyrotoxico-
sis which may secondarily lead to reduced testosterone
from hypogonadism.
The day to day variation in the measurement of serum
testosterone levels encountered in our study could be
avoided as much as possible by recruiting patients with
homozygous sickle cell disease at sickle cell clinics with
high turnover of patients and probably conducting the
assay within a short possible time. The marked diurnal
rhythm in total testosterone should also be taken into
consideration as widely reported [2,20]. As testosterone
concentration may fluctuate markedly both seasonally
and from day to day, it may be judicious to measure
levels on more than one occasion [20]. Importantly, all
testosterone concentrations should be measured at least
twice to make the diagnosis of hypogonadism [21].
Another factor that may contribute to assay of serum
testosterone is variation in types of kit used and thus, it
is important to compare and validate efficiency and
potency of other kits for future detection of serum tes-
tosterone in sickle cell anaemia in Nigeria [21].
The effect of varying climate change could not be
ignored as a possible slightly reducing effect of a tropical
environment on the circulating total testosterone levels
in Zambian African males compared to men of the tem-
perate regions has been reported [22]. In addition, our
study is limited by the inability to totally relying on
information given by patients concerning abstinence
from certain drugs, cigarette smoking and alcoholism
that may affect the testosterone assay. It has been
reported that medications, including those that affect
spermatogenesis such as chemotherapy, anabolic ster-
oids, cimetidine, spironolactone; those that decrease
FSH levels such as phenytoin; and those that decrease
sperm motility such as sulfasalazine and nitrofurantoin
should be avoided prior to serum testosterone assay to
ensure accurate and precise results [20].
The frequent inaccuracies in testosterone measure-
ments reported widely demand standardization of tes-
tosterone assay with the aim of defining performance
criteria that cover the full range of expected values,
from children to adult males and females; define
reference intervals for testosterone in adults and chil-
dren of both sexes; and developing guidelines and proto-
cols to ensure uniform patient preparation and handling
of samples before they are assayed. It is our hope that
f u t u r es t u d i e si nt h i se n v i r onment will eliminate the
mentioned limitations and will involve age, and sex
matched homozygous sickle cell diseases patients and
control subjects with a larger number of subjects. Other
assay methods such as radioimmunoassay (RIA), compe-
titive protein binding methods, established double iso-
tope derivative methods and chromatography mass
spectrometry should be encouraged to reveal other
undiscovered findings about serum testosterone assay in
patients with sickle cell disease as well as confirming
findings of earlier study.
Conclusion
Overall, subjects with HbSS have statistically signifi-
cantly lower mean serum testosterone than HbAA con-
trols. HbSS men are significantly more likely to have
serum testosterone below the normal threshold, result-
ing in delayed onset of puberty and impairment of sex-
ual development observed in HbSS cases.
Limitations
Reliability on the puberty age and history of priapism
provided by the subjects. Effects of climatic change on
subjects and storage of the testosterone kit could not be
totally ignored. Total reliability on the claim of not
being on any medications affecting serum testosterone
assay such as chemotherapy, anabolic steroids, cimeti-
dine, spironolactone, phenytoin, sulfasalazine and nitro-
furantoin as well as abstinence from cigarette smoking
and chronic alcohol consumption could not be
ascertained.
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